摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-(6-methoxy-naphthalen-2-yl)-propionate | 269079-68-7

中文名称
——
中文别名
——
英文名称
3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-(6-methoxy-naphthalen-2-yl)-propionate
英文别名
[3-[2-[(Dimethylamino)methyl]cyclohexen-1-yl]phenyl] 2-(6-methoxynaphthalen-2-yl)propanoate
3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-(6-methoxy-naphthalen-2-yl)-propionate化学式
CAS
269079-68-7
化学式
C29H33NO3
mdl
——
分子量
443.586
InChiKey
WYIDGDCDPCPCIJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.2
  • 重原子数:
    33
  • 可旋转键数:
    8
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.34
  • 拓扑面积:
    38.8
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • Novel esters derived from (rr,ss)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl
    申请人:——
    公开号:US20030100598A1
    公开(公告)日:2003-05-29
    New esters derived from substituted phenyl-cyclohexyl compounds, which are derived from Tramadol, process for obtaining them and their use for preparing a drug with analgesic properties. These new compounds of general formula (I) have a higher analgesic activity, a lower toxicity and a longer effective time period than Tramadol.
    新的酯类化合物来源于取自曲马多(Tramadol)的取代苯基-环己基化合物,其制备方法以及它们用于制备具有镇痛性质的药物。这些新化合物的通式(I)具有比曲马多更高的镇痛活性,更低的毒性和更长的有效时间。
  • NEW ESTERS DERIVED FROM SUBSTITUTED PHENYL-CYCLOHEXYL COMPOUNDS
    申请人:VITA-INVEST, S.A.
    公开号:EP1127871A1
    公开(公告)日:2001-08-29
    New csters derived from substituted phenyl cyclohexyl compounds, which are derived from Tramadol, process for obtaining them and their use for preparing a drug with analgesic properties. These new compounds of general formula (I) have a higher analges activcity, a lower toxicity and a longer effective time period than Tramadol.
    从曲马多衍生的取代苯基环己基化合物的新酯类、获得过程及其在制备具有镇痛特性的药物中的用途。与曲马多相比,这些通式(I)的新化合物具有更高的镇痛活性、更低的毒性和更长的有效期。
  • New esters derived from substituted phenyl-cyclohexyl compounds
    申请人:VITA-INVEST, S.A.
    公开号:EP1219594A1
    公开(公告)日:2002-07-03
    New esters derived from substituted phenylcyclohexyl compounds, which are derived from Tramadol, process for obtaining them and their use for preparing a drug with analgesic properties. These new compounds of general formula (I) have a higher analgesic activity, a lower toxicity and a longer effective time period than Tramadol.
    由取代苯基环己基化合物衍生的新酯类,这些化合物是从曲马多衍生出来的,它们的获得过程以及它们在制备具有镇痛特性的药物中的用途。与曲马多相比,这些通式(I)的新化合物具有更高的镇痛活性、更低的毒性和更长的有效期。
  • Abuse-proofed dosage form
    申请人:GRÜNENTHAL GMBH
    公开号:US10058548B2
    公开(公告)日:2018-08-28
    The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form.
    本发明涉及一种热成型而不变色并可防止滥用的剂型,它包括至少一种断裂强度至少为 500 N 的合成或天然聚合物,以及一种或多种可能被滥用的活性物质。本发明还涉及生产上述剂型的相应方法。
  • Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
    申请人:GRÜNENTHAL GMBH
    公开号:US10064945B2
    公开(公告)日:2018-09-04
    A thermoformed, tamper-resistant pharmaceutical dosage form comprises: a) a pharmacologically active ingredient; b) a polyalkylene oxide having a weight average molecular weight of more than 200,000 g/mol; and c) a zinc component, wherein the content of said zinc component is at least 1 ppm, relative to the total weight of the pharmaceutical dosage form. When the pharmacologically active ingredient is effective against pain, the pharmaceutical dosage form may be used in a method of treating pain. When the pharmacologically active ingredient has abuse potential, the pharmaceutical dosage form may be used in a method of reducing the incidence of the abuse of said pharmacologically active ingredient.
    一种热成型防篡改药物剂型包括 a) 药理活性成分; b) 聚环氧烷,其重量平均分子量大于 200,000 克/摩尔;以及 c) 锌成分,其中所述锌成分的含量相对于药物剂型的总重量至少为 1 ppm。 当药理活性成分对疼痛有效时,药物剂型可用于治疗疼痛的方法。当药理活性成分具有滥用潜力时,药物剂型可用于降低所述药理活性成分滥用发生率的方法。
查看更多